{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihqdxrkmz7rjqw42lxxokmuwm3zj46wp7iyt33ypfy5x3pncuixc4",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mg3vvsjovrx2"
  },
  "path": "/2026/03/02/xellsmart-receives-fourth-consecutive-us-fda-china-nmpa-ind-clearance-for-msa-p-ipsc-derived-cell-therapy/",
  "publishedAt": "2026-03-02T14:10:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SUZHOU, China, March 2, 2026 /PRNewswire/ — In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the […]",
  "title": "XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy"
}